2221. Active Substance Use Should Not Be a Contraindication for Hepatitis C Treatment in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients

摘要

BackgroundHepatitis C virus (HCV) infection disproportionately affects HIV-infected patients. HIV/HCV Co-infected patients are more likely to develop advanced liver disease/cirrhosis in comparison to mono-infected patients. HCV treatment with new oral direct-acting antiviral (DAA) therapy is effective in HIV/HCV co-infected patients with cure rate similar to mono-infected patients. Despite the effective treatments, only small portion of co-infected patients are treated for HCV infection. One of the known barriers to HCV treatment is active substance abuse. However, there is limited information about outcomes of HCV treatment with active substance abuse in HIV/HCV co-infected patients. Our primary aim was to evaluate Hepatitis C treatment outcomes in HIV/HCV co-infected patients with active substance abuse (ASA).